Immunome Inc reports results for the quarter ended September 30 - Earnings Summary

• Immunome Inc IMNM.OQ reported a quarterly adjusted loss of 67 cents​​ per share for the quarter ended September 30. The mean expectation of six analysts for the quarter was for a loss of 56 cents per share. Wall Street expected results to range from -77 cents to -35 cents per share.

• Revenue fell 18.4% to $2.91 million from a year ago; analysts expected $2.13 million.

• Immunome Inc's reported EPS for the quarter was a loss of 78 cents​.

• The company reported a quarterly loss of $47.1 million.

• Immunome Inc shares had fallen by 14.6% this quarter and gained 16.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Immunome Inc is $34.00

This summary was machine generated from LSEG data November 14 at 04:19 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)